ForteBio Introduces the Octet(TM) System for Antibody and Protein Therapeutics Development
Share:
MENLO PARK, Calif., Nov. 29 /-- ForteBio, Inc. today announced the commercial introduction of the company's first product, the Octet(TM) System for label-free, real-time detection and analysis of molecular interactions. The next generation of analytical tools for life science research, Octet accelerates antibody development by generating real-time quantitative and kinetics results quickly and easily. Ready to use, consumable biosensors provide a cost-effective way to make critical measurements even in crude samples and at early stages in antibody development. New applications are easily addressed by offering new biosensors with modified surface chemistries.
The ForteBio Octet System is based on a proprietary technique called BioLayer Interferometry (BLI). The Octet System incorporates a sensitive optical detector and a unique series of application-specific biosensor consumables. The system was validated in beta testing conducted at Genzyme Corporation, KaloBios Pharmaceuticals, Inc., Raven biotechnologies, inc. and a number of other leading biotechnology and pharmaceutical companies. Researchers achieved success in the real-time analysis of therapeutic antibodies and proteins; and Octet provides unique capabilities that will allow expansion into a number of different life-science applications. Future generations of BLI technology will be optimized for small molecule detection and clinical immunogenicity.
Raven has replaced ELISA methods with ForteBio's Octet System as the primary assay during cell culture and process development. "Octet gives us product titres quickly and accurately from crude cell culture samples," commented Dr. Hugh Graham, head of upstream manufacturing at Raven. "This helps us acquire more data in real time and thus improve our processes rapidly."
"By collaborating with scientists/researchers at our biotech and pharma beta sties, we were able to optimize our technology to meet their specific needs," stated Winnie H. Wan, Ph.D., President and Chief Executive Officer of ForteBio. "We are very pleased with the acceptance of our proprietary technology and expect that the Octet System will be a valuable tool in the selection and characterization of therapeutic antibodies in development."
ForteBio will be presenting two technical posters, and the Octet System will be available for demonstration, at the IBC Antibody Therapeutics meeting in San Diego December 6 through December 8.
To inquire about purchasing an Octet System, please contact Stephen Oldfield at 650-322-1360, ext. 135 or via email at soldfield@fortebio.com.
About ForteBio, Inc.
ForteBio is a venture-capital funded life science company developing analytical systems to provide rapid, real-time results for protein quantification and characterization of protein-protein interaction. These systems enable real-time analysis of biomolecular interactions in micro-volume sample sizes, providing information on affinity, kinetics and concentration. Most importantly, ForteBio's analytical capabilities provide greater value in applications where existing methods have limitations in throughput, performance and cost. The company is located in Menlo Park, California. For more information, please visit www.fortebio.com.
NOTE: Octet is a trademark of ForteBio, Inc.
Source: ForteBio, Inc.
CONTACT: Winnie H. Wan, Ph.D., President & CEO, +1-650-322-1360, ext. 111, or wwan@fortebio.com, or Stephen Oldfield, Ph.D., VP, Marketing & Sales, +1-650-322-1360, ext. 135, both of ForteBio, Inc.
Web site: www.fortebio.com/
